NEUKIO BIOTHERAPEUTICS
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general-purpose spot immune cell products, and is committed to providing effective therapeutic drugs for cancer patients around the world.
NEUKIO BIOTHERAPEUTICS
Industry:
Biotechnology
Founded:
2021-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Status:
Active
Total Funding:
90 M USD
Similar Organizations
ImmPACT Bio
ImmPACT Bio USA is developing novel cell therapies for treating cancer.
Current Employees Featured
Founder
Investors List
Yahui Precision Medicine Fund
Yahui Precision Medicine Fund investment in Series A - Neukio Biotherapeutics
Kuanyu Private Equity
Kuanyu Private Equity investment in Series A - Neukio Biotherapeutics
CD Capital
CD Capital investment in Series A - Neukio Biotherapeutics
Lilly Asia Ventures
Lilly Asia Ventures investment in Series A - Neukio Biotherapeutics
Sherpa Venture Capital
Sherpa Venture Capital investment in Series A - Neukio Biotherapeutics
IDG Capital
IDG Capital investment in Series A - Neukio Biotherapeutics
Sherpa Venture Capital
Sherpa Venture Capital investment in Angel Round - Neukio Biotherapeutics
Lilly Asia Ventures
Lilly Asia Ventures investment in Angel Round - Neukio Biotherapeutics
IDG Capital
IDG Capital investment in Angel Round - Neukio Biotherapeutics
More informations about "Neukio Biotherapeutics"
NEUKIO
Neukio Biotherapeutics focuses on development of next generation allogenic cell therapies via the iPSC-CAR-NK axis, through internal discovery and external collaboration, with emphasis on …See details»
Neukio Biotherapeutics - Crunchbase Company Profile & Funding
Neukio Biotherapeutics is an immune cell drug developer, focusing on the research and development and industrialization of immune cell drugs, developing iPSC-CAR-NK general …See details»
About Neukio-NEUKIO
Neukio Biotherapeutics Established operation in June 2021 at the Simbay Life Science Park in Shanghai Free Trade Zone, focuses on development of allogeneic cell therapies for solid …See details»
Neukio Biotherapeutics Company Profile 2024: …
Developer of allogenic immune cell therapies for treatment of cancer.See details»
Neukio Biotherapeutics completed Series A-1 …
Sep 2, 2022 · Neukio, founded at the Simbay Park in Shanghai Pilot Free Trade Zone (China) in June 2021, is an innovative biotherapeutic company focusing on the development and commercialization of next generation immune cell therapy.See details»
Neukio Biotherapeutics Co., Ltd. - Drug pipelines, Patents, Clinical ...
At the helm of the Shanghai-based Neukio Biotherapeutics is a leader with experience in the CAR-T cell therapy market, with Richard Liqun Wang having previously served as chief …See details»
Neukio Biotherapeutics - Funding, Financials, Valuation & Investors
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.See details»
Neukio Biotherapeutics - VentureRadar
Neukio focuses on the development and commercialization of allogenic cell therapies from the iPSC-CAR-NK axis, through a combined approach of in-house innovation and external …See details»
Neukio Biotherapeutics completed Series A-1 …
Sep 2, 2022 · Neukio, founded at the Simbay Park in Shanghai Pilot Free Trade Zone (China) in June 2021, is an innovative biotherapeutic company focusing on the development and commercialization of next generation immune cell therapy.See details»
Neukio Bio raises $50m for allogenic CAR-T therapies
Neukio Biotherapeutics has completed a $50 million Series A-1 funding to support development of its cell therapy molecules.See details»
Press Releases-NEUKIO
Dr. Richard Liqun Wang, Founder, Chairman, and CEO of Neukio Biotherapeutics, presented the current state, trends, bottlenecks, and prospects of Cell and Gene Therapy (CGT) research and development in China.See details»
Neukio Biotherapeutics completed its $40m Angel round financing ...
Jul 30, 2021 · Neukio focuses on the development and commercialization of allogenic cell therapies from the iPSC-CAR-NK axis, through a combined approach of in-house innovation …See details»
Neukio Biotherapeutics - Contacts, Employees, Board Members, …
Neukio Biotherapeutics is a developer of allogenic immune cell therapies for treatment of cancer.See details»
Neukio Biotherapeutics completed Series A-1 financing, to
Sep 2, 2022 · Neukio Biotherapeutics, a company committed to developing novel cell therapy products, announces it has closed $50 million in a Series A-1 funding round.See details»
Neukio Biotherapeutics completed its $40m Angel round
Neukio Biotherapeutics, a newly established company, recently announced the completion of its $40m Angel round of financing led by Lilly Asia Venture (LAV), with the participation of IDG …See details»
Neukio Biotherapeutics has completed $40m Angel round of …
Oct 25, 2021 · Neukio focuses on the development and commercialization of allogenic cell therapies from the iPSC-CAR-NK axis, through a combined approach of in-house innovation …See details»
EdiGene and Neukio Enter Collaboration to Develop Next …
Feb 9, 2022 · Neukio aims for treating cancer patients worldwide, through a combined approach of in-house innovation and external collaboration with world leading partners. In December …See details»
Neukio Bio of Shanghai Raises $40 Million for Universal CAR-T …
Neukio Biotherapeutics, a Shanghai startup, completed a $40 million Angel round to develop universal CAR-T therapies. The round was led by Lilly Asia Venture, with participation from …See details»
Core Team-NEUKIO
All contents Neukio Biotherapeutics Co, Ltd. All right reserved. Shanghai ICP prepared No. 2021033013-1 ...See details»
Neukio Biotherapeutics completed Series A-1 financing, to …
Sep 2, 2022 · Neukio, founded at the Simbay Park in Shanghai Pilot Free Trade Zone (China) in June 2021, is an innovative biotherapeutic company focusing on the development and …See details»